Targinta selects lead drug candidate for triple-negative breast cancer
The preclinical stage oncology biotech company Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin a10b1. TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triple-negative breast cancer models. Xintela, of which Targinta is a wholly […]
Xintela signs with Australian CRO for clinical study
Xintela announces today that the company has signed a contract with GreenLight Clinical, an Australian Contract Research Organisation (CRO) to conduct Xintela’s First-in-Human study using the stem cell product XSTEM. Xintela’s First-in-Human study with the stem cell product XSTEM, a combined phase I/II clinical study on patients with knee osteoarthritis, will be conducted in Australia […]
Xintela incorporates subsidiary in Australia
Xintela has formed a wholly owned subsidiary, Xindu Pty Ltd, in Australia, which will administer the company’s upcoming clinical study on osteoarthritis patients. Xintela has previously announced that the company is planning a clinical study (Phase I / IIa) in Australia where the stem cell product XSTEM® will be tested for the treatment of osteoarthritis. […]
Xintela’s GMP facility approved for manufacturing of cell therapy products
Xintela announces today that the company has received permission from the Medical Products Agency to produce cell therapy products, so-called advanced therapy drugs (ATMPs), in its own GMP facility. – It is a key achievement from the team that the manufacturing permit is now in place. This means we can now start to manufacture our […]
Xintela to develop stem cell therapy for difficult-to-heal wounds
Xintela announces today that the company will develop its stem cell product XSTEM® for the treatment of difficult-to-heal (chronic) wounds. In collaboration with The Burn Center at Linköping University Hospital, Xintela has found that XSTEM has excellent wound healing capability in a preclinical model and is now planning for a clinical trial on patients with […]
Xintela’s stem cell product XSTEM repairs cartilage damage in preclinical model
Xintela announces that the company’s stem cell product XSTEM® regenerates cartilage in a preclinical animal model. The study, a research collaboration between Xintela and the University of Copenhagen, designed to increase the understanding of XSTEM’s mechanisms of action, confirms XSTEM’s potential as a treatment for osteoarthritis. Xintela has previously shown that the company’s integrin α10-selected […]
Xintela GMP inspection for manufacturing license completed
Lund, Sweden, 12 April 2021 – Xintela announces today completion of the inspection by the Swedish Medical Products Agency for a license to produce cell therapy products, also known as Advanced Therapy Medicinal Products (ATMPs), for clinical studies. Xintela has developed and patented the stem cell product platform XSTEM and built its own GMP (Good […]
Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK
Lund, Sweden, 6 April 2021 – Xintela today announces the positive outcome of the preclinical ARDS (Acute Respiratory Distress Syndrome) study partly financed by Vinnova. The results of the study demonstrate the potential of the company’s stem cell product XSTEM® in the treatment of ARDS, a life-threatening lung complication that can affect severely ill COVID-19 […]
Xintela gets tissue establishment license
Lund, Sweden, 19 March 2021 – Xintela announces today that the company has received a tissue establishment license from the Swedish Medical Products Agency for handling human tissues and cells for manufacturing medicinal products. In order to conduct activities that use human tissues and cells for the manufacture of medicinal products, a tissue establishment license […]
Xintela gets patent grant in Europe for XSTEM stem cell product
Lund, Sweden, 17 March 2021 – Xintela announces that the European Patent Office (EPO) has today approved the patent application for the company’s stem cell product XSTEM® consisting of integrin 10-selected mesenchymal stem cells. Xintela previously announced (October 29, 2020) the preliminary approval of its European patent application from the EPO for the XSTEM stem […]
